☆ 4.7 Article

Quantitative Analysis of Anti-N and Anti-S Antibody Titers of SARS-CoV-2 Infection after the Third Dose of COVID-19 Vaccination

VACCINES (2022)

Related references

Note: Only part of the references are listed.

Article Biochemistry & Molecular Biology

The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic

Markus Hoffmann et al.

Summary: The Omicron variant of SARS-CoV-2 is spreading rapidly and shows resistance to most therapeutic antibodies. It also evades neutralization by antibodies induced by infection or vaccination more efficiently than the Delta variant. This suggests that therapeutic antibodies may not be effective against the Omicron variant, and double vaccination with BNT162b2 may not provide adequate protection against severe disease caused by this variant.

CELL (2022)

Add to Collection

Article Chemistry, Medicinal

Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance

Jiahui Chen et al.

Summary: The Omicron variant of the SARS-CoV-2 virus has caused global panic due to its high infectivity and ability to escape vaccines. A comprehensive analysis using an artificial intelligence model and antibody structure analysis reveals that Omicron may be over 10 times more contagious than the original virus and has an 88% likelihood of vaccine escape. This study highlights the importance of developing mutation-proof vaccines and antibodies.

JOURNAL OF CHEMICAL INFORMATION AND MODELING (2022)

Add to Collection

Article Immunology

Clinical Utility of Elecsys Anti-SARS-CoV-2 S Assay in COVID-19 Vaccination: An Exploratory Analysis of the mRNA-1273 Phase 1 Trial

Simon Jochum et al.

Summary: This study assessed the clinical utility of the Roche Elecsys Anti-SARS-CoV-2 S assay in evaluating the immune response after mRNA-1273 vaccination. The results suggest that ACOV2S can be used to quantitatively assess vaccine-induced SARS-CoV-2 antibodies and may indicate the presence of neutralizing antibodies.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Immunology

SARS-CoV-2 Spike and Neutralizing Antibody Kinetics 90 Days after Three Doses of BNT162b2 mRNA COVID-19 Vaccine in Singapore

Chin Shern Lau et al.

Summary: Post-booster vaccination led to significant increase in antibody titers at 30 days, which were higher than peak levels post-second dose, suggesting a prolonged antibody response with half-lives estimated to be 44/58 days.

VACCINES (2022)

Add to Collection

Article Infectious Diseases

Humoral immunity in dually vaccinated SARS-CoV-2-naive individuals and in booster-vaccinated COVID-19-convalescent subjects

Vivian Gluck et al.

Summary: The immune response to COVID-19 vaccination differs between naive vaccinees and those who were previously infected with SARS-CoV-2. Longitudinal quantitative and qualitative serological differences in these two distinct immunological subgroups in response to vaccination are currently not well studied.

INFECTION (2022)

Add to Collection

Article Biochemical Research Methods

Clinical and analytical evaluation of the Abbott AdviseDx quantitative SARS-CoV-2 IgG assay and comparison with two other serological tests

Gabriel N. Maine et al.

Summary: The Abbott AdviseDx SARS-CoV-2 IgG II assay demonstrates high specificity and sensitivity, making it a valuable tool for quantitatively assessing the humoral immune response to COVID-19 infection and vaccination. Monitoring changes in IgG antibody levels post-viral infection is crucial, and this assay proves to be reliable in this aspect.

JOURNAL OF IMMUNOLOGICAL METHODS (2022)

Add to Collection

Article Multidisciplinary Sciences

Effect of the third dose of BNT162b2 vaccine on quantitative SARS-CoV-2 spike 1-2 IgG antibody titers in healthcare personnel

Maria Elena Romero-Ibarguengoitia et al.

Summary: This study found that a third dose of the BNT162b2 vaccine administered six months after the original regimen increased the quantitative SARS-CoV-2 spike 1-2 IgG antibody titers. The booster dose was well tolerated and caused fewer adverse events compared to the first two doses, although specific symptoms such as fatigue, myalgia, arthralgia, fever, and adenopathy were more common.

PLOS ONE (2022)

Add to Collection

Article

Comparative evaluation of SARS-CoV-2 IgG assays against nucleocapsid and spike antigens

Mitra Rezaei et al.

Human Antibodies (2021)

Add to Collection

Article Infectious Diseases

Comparison of an inactivated Covid19 vaccine-induced antibody response with concurrent natural Covid19 infection

Emel Azak et al.

Summary: This study compared the antibody response between vaccinated individuals and naturally infected patients, finding that the antibody levels in the vaccinated group were lower than in the patient group, and that there was a disadvantageous decrease in antibody titers over time.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Article Microbiology

Comparison of the Results of Five SARS-CoV-2 Antibody Assays before and after the First and Second ChAdOx1 nCoV-19 Vaccinations among Health Care Workers: a Prospective Multicenter Study

Seri Jeong et al.

Summary: The study evaluated serological positivity to SARS-CoV-2 antibodies after the second dose of AstraZeneca vaccine, finding a high positivity rate of 98.2% to 100.0% and increased antibody titers in different assays. Adverse reactions decreased after the second dose, potentially informing decisions regarding vaccination strategies and immunoassay use.

JOURNAL OF CLINICAL MICROBIOLOGY (2021)

Add to Collection

Letter Medicine, General & Internal

Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2

Saman Saadat et al.

Summary: This study compared the titers of binding and neutralizing antibodies in healthcare workers previously infected with SARS-CoV-2 after receiving a single dose of mRNA coronavirus vaccine.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Letter Medicine, General & Internal

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals

Charlotte Manisty et al.

LANCET (2021)

Add to Collection

Letter Medicine, General & Internal

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Florian Krammer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

News Item Medicine, General & Internal

Covid-19: People who have had infection might only need one dose of mRNA vaccine

Jacqui Wise

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Immunology

Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination

Rafael Assis et al.

Summary: Analysis of two ongoing COVID-19 longitudinal serological surveys in Orange County, CA revealed a significant increase in antibody levels post-vaccination, with mRNA vaccination inducing a stronger and broader antibody response compared to SARS-CoV-2 infection. Nucleocapsid protein antibodies can differentiate vaccinees, and previously infected individuals exhibit higher antibody titers to the vaccine.

NPJ VACCINES (2021)

Add to Collection

Letter Medicine, General & Internal

SARS-CoV-2 Antibody Response in Persons with Past Natural Infection

Gabriele Anichini et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

Yinon M. Bar-On et al.

Summary: After receiving a third dose of the BNT162b2 mRNA vaccine, Israeli residents aged 60 and above who had previously received two doses of the vaccine saw significantly lower rates of confirmed Covid-19 infection and severe illness compared to those who did not receive a booster shot, indicating the effectiveness of the booster dose in reducing infection and severe illness.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Anti-SARS-CoV-2 Antibodies Testing in Recipients of COVID-19 Vaccination: Why, When, and How?

Giuseppe Lippi et al.

Summary: Although testing for anti-SARS-CoV-2 antibodies in recipients of COVID-19 vaccination can provide benefits such as assessing baseline seroprevalence, identifying non-responders, and detecting antibody decay, challenges like unclear equivalence between antibody titer, neutralizing activity, and vaccine efficiency; lack of cost-effective analyses; and increased laboratory workload remain. A potential solution involves prioritizing testing for high-risk individuals and those with lower vaccine immunogenicity.

DIAGNOSTICS (2021)

Add to Collection

Article Infectious Diseases

Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs

Jan Van Elslande et al.

CLINICAL MICROBIOLOGY AND INFECTION (2020)

Add to Collection

Article Immunology

Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients

Baoqing Sun et al.

EMERGING MICROBES & INFECTIONS (2020)

Add to Collection

Review Virology

The Coronavirus Nucleocapsid Is a Multifunctional Protein

Ruth McBride et al.

VIRUSES-BASEL (2014)

Add to Collection

Article Psychology, Clinical

Useful effect size interpretations for single case research

Richard I. Parker et al.

BEHAVIOR THERAPY (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.